Aprepitant - StatPearls - NCBI Bookshelf
2024年1月11日 · Aprepitant and fosaprepitant are drugs used to prevent nausea and vomiting in cancer patients. Aprepitant can be taken orally or intravenously (IV), whereas fosaprepitant is an IV prodrug. Aprepitant was initially developed to prevent chemotherapy-induced nausea and vomiting (CINV).
Aprepitant: Uses, Interactions, Mechanism of Action - DrugBank …
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of …
Aprepitant - Wikipedia
Aprepitant is used to prevent chemotherapy-induced nausea and vomiting and to prevent postoperative nausea and vomiting. [5] . It may be used together with ondansetron and dexamethasone. [5] Aprepitant is classified as an NK 1 antagonist because it blocks signals given off by NK 1 receptors.
Antiemetic Neurokinin-1 Receptor Blockers - StatPearls - NCBI Bookshelf
2024年1月11日 · Examples of NK-1 receptor inhibitors include aprepitant, rolapitant, casopitant, netupitant, maropitant, and fosaprepitant. Rolapitant, a recently developed highly selective NK-1 receptor antagonist, boasts an exceptionally extended plasma half-life (T1/2) of 180 hours.
Fosaprepitant: Uses, Interactions, Mechanism of Action
Fosaprepitant is an antiemetic drug used in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting caused by chemotherapy. Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant.
CINVANTI® (aprepitant) injectable emulsion | Official HCP Site
3-day oral aprepitant with MEC (≥1% and greater than standard therapy): fatigue and eructation. Single-dose fosaprepitant with HEC: generally similar to 3-day oral aprepitant. In addition, infusion site reactions (3%) occurred.
Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and …
Aprepitant (and its prodrug fosaprepitant) is a neurokinin-1 receptor antagonist approved more than a decade ago for the prevention of chemotherapy-induced nausea and vomiting (CINV). …
Aprepitant - PubMed
2024年1月11日 · Aprepitant was initially developed to prevent chemotherapy-induced nausea and vomiting (CINV). However, its applications have since broadened to include postoperative nausea and vomiting (PONV).
APONVIE is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. APONVIE has not been studied for...
2010年5月20日 · Aprepitant is an NK-1 receptor antagonist that crosses the blood–brain barrier to exert its antiemetic effect [10] and has been approved for the prevention of CINV in patients receiving highly emetogenic chemotherapy and MEC.